Phaseline

Companies › Cognition Therapeutics

Cognition Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Neurology; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CT1812
sigma-2 receptor ligand
–Phase 2Early Alzheimer's DiseaseMay 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05531656CT1812Phase 2Early Alzheimer's DiseaseNeurologyMay 2027

From the company's SEC filings

Cash of $31m on 2026-09-30; operating cash outflow about $16m a year; runway about 23 months at that burn, to Sep 2028; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Satellos Bioscience Coya Therapeutics PepGen DiaMedica Therapeutics IGC Pharma

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.